ArticleJournal for immunotherapy of cancer2026

Phase 1 study of KHK2455, a long-acting, potent and selective IDO1 inhibitor, in combination with avelumab in patients with locally advanced or metastatic urothelial carcinoma.

Yousef Zakharia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.